Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

Clinical pharmacology and therapeutics - 1 Apr 2007

Hamberg A-K, Dahl M-L, Barban M, Scordo M G, Wadelius M, Pengo V, Padrini R, Jonsson E N

Abstract excerpt

The aim of this study was to characterize the relationship between warfarin concentrations and international normalized ratio (INR) response and to identify predictors important for dose individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and VKORC1 genotypes from 150 patients were used to develop a population pharmacokinetic/pharmacodynamic model in NONMEM. The anticoagulant response was best...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mixed Function Oxygenases

Share to Pharmacokinetics

Share to Population

Share to Stereoisomerism

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 17301738
DOI: 10.1038/sj.clpt.6100084

Genes

VKORC1
MAX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.PMID 17301738Read ↗

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.Semantic proximity Read ↗

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.Semantic proximity Read ↗

Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.Semantic proximity Read ↗

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Semantic proximity Read ↗

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Semantic proximity Read ↗

Genotype-guided dosing of warfarin through modeling and simulation.Semantic proximity Read ↗

Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.Semantic proximity Read ↗

A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments.Semantic proximity Read ↗

New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.Semantic proximity Read ↗

The Creating an Optimal Warfarin Nomogram (CROWN) Study.Semantic proximity Read ↗

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Semantic proximity Read ↗

Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.